Efficacy of Dapagliflozin versus Empagliflozin on Glycemic Control and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Saravanan S; Maheshwari P; Karthickeyan K; Shanmugasundaram Palani

doi:10.37022/wjcmpr.v8i2.415

Authors

Saravanan S Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, India.
Maheshwari P Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, India.
Karthickeyan K Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, India.
Shanmugasundaram Palani Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, India

Abstract

The aim of the current study was to compare clinical effectiveness and safety profile of Empagliflozin and Dapagliflozin in patients with type 2 diabetes mellitus.This was a prospective comparative study involving a total of n = 120 patients with type 2 diabetes mellitus, who were split into two equal groups; Group A (Empagliflozin, n = 60) and Group B (Dapagliflozin, n = 60). The baseline parameters were fasting blood glucose (FBG), postprandial blood glucose (PPBG), and HbA1c. There were follow-up assessments after 12 weeks. Paired and unpaired t-tests were used to perform statistical analysis, and p < 0.05 was used as a significant value.At baseline, mean HbA1c levels were comparable between Group A (8.6 ± 0.7%) and Group B (8.5 ± 0.6%). After 12 weeks, HbA1c reduced to 7.1 ± 0.5% in the empagliflozin group and 7.4 ± 0.6% in the dapagliflozin group (p < 0.05).Group A experienced a reduction in FBG, 168 ± 22 mg/dL to 128 ± 18 mg/dL, and Group B experienced the same reduction, 165 ± 20 mg/dL to 135 ± 19 mg/dL, but no serious events were reported. The two drugs had a remarkable glycaemic improvement, albeit with Empagliflozin slightly better in reducing HbA1c than Dapagliflozin. They both were well tolerated.

Keywords:

Diabetes Mellitus type 2, SGLT2, Empagliflozin, Dapagliflozin, HbA1c, Glycaemic control, Comparative study

DOI

https://doi.org/10.37022/wjcmpr.v8i2.415

References

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

2. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.

3. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.

4. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.

5. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.

6. Wilding JPH, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012;156(6):405-415.

7. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.

8. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.

9. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.

10. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(8):606-617.

11. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.

12. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit. Cell Metab. 2018;28(3):350-359.

13. Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, et al. Mediators of the improvement in heart failure outcomes with empagliflozin in EMPA-REG OUTCOME. ESC Heart Fail. 2021;8(6):4517-4527.

14. Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, et al. DECLARE–TIMI 58: Participants’ baseline characteristics. Diabetes Obes Metab. 2018;20(5):1102-1110.

15. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: Analysis from DECLARE-TIMI 58 Study. Diabetes Care. 2020;43(2):468-475.

16. Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11(4):233-241.

17. Muskiet MHA, van Raalte DH, van Bommel EJM, Smits MM, Tonneijck L. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 2015;3(12):928-929.

18. Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes. J Am Soc Nephrol. 2018;29(11):2755-2769.

19. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Bluhmki E, et al. Rationale, design, and baseline characteristics of EMPA-REG OUTCOME. Cardiovasc Diabetol. 2014;13:102.

20. Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, et al. Effects of empagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes. Circulation. 2019;139(11):1384-1395.